H
Hernan Valdez
Researcher at Boehringer Ingelheim
Publications - 81
Citations - 3966
Hernan Valdez is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Viral load & Lymphocyte. The author has an hindex of 31, co-authored 73 publications receiving 3809 citations. Previous affiliations of Hernan Valdez include Indiana University & University Hospitals of Cleveland.
Papers
More filters
Journal ArticleDOI
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B. Hicks,Pedro Cahn,David A. Cooper,Sharon Walmsley,Christine Katlama,Bonaventura Clotet,Adriano Lazzarin,Margaret Johnson,Dietmar Neubacher,Douglas L. Mayers,Hernan Valdez +10 more
TL;DR: In this article, the authors compared the efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir plus an optimised background regimen with that of an investigator-selected Ritonavirus-boosted comparator protease inhibitors (CPI-ritonavir) in such patients.
Journal ArticleDOI
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
Peter W. Hunt,Steven G. Deeks,Benigno Rodriguez,Hernan Valdez,Starley B. Shade,Donald I. Abrams,Mari M. Kitahata,Melissa R. Krone,Torsten B. Neilands,Richard J. Brand,Michael M. Lederman,Jeffrey N. Martin +11 more
TL;DR: Most patients who achieve and maintain viral suppression on HAART continue to experience CD4 T-cell gains through 4 years of therapy, indicating the immune system's capacity forCD4 T lymphocyte restoration is not limited by low pre-therapy CD4 counts.
Journal ArticleDOI
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function
Lucileia Teixeira,Hernan Valdez,Joseph M. McCune,Richard A. Koup,Andrew D. Badley,Andrew D. Badley,Marc K. Hellerstein,Marc K. Hellerstein,Laura A. Napolitano,Daniel C. Douek,Georgina Mbisa,Georgina Mbisa,Steven G. Deeks,Jeffrey M. Harris,Jason D. Barbour,Barry H. Gross,Isaac R. Francis,Robert A. Halvorsen,Robert Asaad,Michael M. Lederman +19 more
TL;DR: Poor CD4 T cell increases observed in some patients with good virologic response to HAART may be caused by failure of thymic T cell production.
Journal ArticleDOI
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.
Hernan Valdez,Elizabeth Connick,Elizabeth Connick,Kimberly Y. Smith,Kimberly Y. Smith,Michael M. Lederman,Ronald J. Bosch,Ronald J. Bosch,Ryung S. Kim,Ryung S. Kim,Marty St. Clair,Marty St. Clair,Daniel R. Kuritzkes,Daniel R. Kuritzkes,Harold A. Kessler,Harold A. Kessler,Lawrence Fox,Lawrence Fox,Michelle Blanchard-Vargas,Michelle Blanchard-Vargas,Alan L. Landay,Alan L. Landay +21 more
TL;DR: Immune restoration was incomplete in patients who started HAART with moderately advanced HIV-1 disease and most changes occurred during the first year, suggesting that this degree of suppression of HIV- 1 replication alone will not suffice to restore immune competence.
Journal ArticleDOI
Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection
Christoph Lange,Michael M. Lederman,Kathy Medvik,Robert Asaad,Mary Wild,Robert C. Kalayjian,Hernan Valdez +6 more
TL;DR: Delaying the initiation of HAART in chronic HIV-1 infection results in impaired functional immune restoration despite normalization of circulating CD4 T-cell numbers, suggesting the ability to respond to vaccination is still uncertain.